Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ATX968
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Bristol Myers Squibb
Deal Size : $75.0 million
Deal Type : Series C Financing
Accent Therapeutics Raises $75 Million Series C for Precision Cancer Therapies
Details : The net proceeds will support Accent's first-in-class DHX9 inhibitor for triple-negative breast cancer and ovarian cancer, alongside a potentially best-in-class KIF18A inhibitor.
Brand Name : ATX968
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : ATX968
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Bristol Myers Squibb
Deal Size : $75.0 million
Deal Type : Series C Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The presentation will describe the first identification of potent and selective small molecule inhibitors of DHX9 that demonstrate tumor cell killing in both in vitro and in vivo preclinical cancer models.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ipsen
Deal Size : $446.0 million
Deal Type : Collaboration
Details : This collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities and proven track record in Oncology medicine development and commercialization.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 18, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ipsen
Deal Size : $446.0 million
Deal Type : Collaboration
Lead Product(s) : METTL3
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : EcoR1 Capital
Deal Size : $63.0 million
Deal Type : Series B Financing
Accent Therapeutics nabs $63M for RNA cancer push
Details : Proceeds from the financing will be used to advance the development of Accent’s novel therapies targeting RNA-modifying proteins (RMPs), including its lead programs METTL3 and ADAR1.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 23, 2020
Lead Product(s) : METTL3
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : EcoR1 Capital
Deal Size : $63.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?